ShanuModiMD

Breast Cancer

Associate Professor, Medicine, Weill Cornell Medical College Associate Attending, Memorial Sloan Kettering Cancer Center

Request Appointment

Overview of Dr. Modi

Dr. Shanu Modi is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from University of Alberta Faculty of Medicine and has been in practice 22 years. Dr. Modi accepts several types of health insurance, listed below. She is one of 493 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
300 East 66th Street
Floors 1 - 4
New York, NY 10065
Book by Phone+1(985) 492-0919

Education & Training

University of AlbertaClass of 1995

Certifications & Licensure

FL State Medical License 2022 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2004 - 2025

Clinical Trials

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2009 Aug 01
Completed
Phase 1, Phase 2
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer Start of enrollment: 2011 Jan 01
Completed
Phase 2
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies Start of enrollment: 2011 Jul 06
Completed
Phase 1
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06
Completed
Phase 1
A Safety Study of SGN-LIV1A in Breast Cancer Patients Start of enrollment: 2013 Oct 22
Completed
Phase 1
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 1
Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer Start of enrollment: 2014 Jun 16
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

575 citations
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
Pedram Razavi, Matthew T. Chang, Guotai Xu, Chaitanya Bandlamudi, Dara S. Ross
Cancer Cell. 2018-09-10
575 citations
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu
The New England Journal of Medicine. 2020-05-29
175 citations
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia
CA. 2021-11-12

Lectures

A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigatorâ€™s choice in HER2-low breast cancer.
2019 ASCO Annual Meeting - 6/1/2019
Less Is More: A Targeted Difference
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

T-dXd Benefits Persist for HER2-Low Breast CancerNovember 8th, 2023
These Major Breakthroughs of 2022 Will Affect Health for Years to ComeDecember 25th, 2022
Breast Cancer Research in 2022: 10 Breakthroughs in Detection and TreatmentOctober 21st, 2022
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment